Previous 10 | Next 10 |
– Data demonstrate potent efficacy of small-molecule OX2R agonists in a non-clinical model of narcolepsy type 1 (NT1) – – Company recognizes World Narcolepsy Day on September 22 nd – BOSTON and LONDON, Sept. 20, 2022 (GLOBE NEWSWIRE)...
The following slide deck was published by Centessa Pharmaceuticals plc in conjunction with this event. For further details see: Centessa Pharmaceuticals (CNTA) Presents at the Morgan Stanley 20th Annual Global Healthcare Conference - Slideshow
The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Centessa Pharmaceuticals' ( NASDAQ: CNTA ) SerpinPC to treat hemophilia B. The U.K.-based company said in a Sept. 14 press release that it plans to begin registrational studies of SerpinPC i...
- Registrational studies planned to start in 4Q 2022 - - Two-year data from Phase 2a Open Label Extension study expected in 4Q 2022 - BOSTON and LONDON, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical comp...
BOSTON and LONDON, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop, and ultimately deliver impactful medic...
The following slide deck was published by Centessa Pharmaceuticals plc in conjunction with this event. For further details see: Centessa Pharmaceuticals (CNTA) Investor Presentation - Slideshow
Centessa Pharmaceuticals ( NASDAQ: CNTA ) turned lower in the pre-market Friday after Morgan Stanley downgraded the clinical-stage biotech to Underweight from Overweight, noting the recent setbacks for the U.K. company's late-stage assets. Recalling that Centessa's ( CNT...
Centessa Pharmaceuticals press release ( NASDAQ: CNTA ): Q2 GAAP EPS of -$0.69. Cash and Cash Equivalents: $484.2 million as of June 30, 2022, which the Company expects will fund operations into 2026, without drawing on the remaining available tranches under the Oberl...
- Registrational studies of SerpinPC for treatment of Hemophilia B planned for 2H of 2022 – - Oncology pipeline advancing with novel LockBody® technology – - Announces discontinuation of ZF874 for AATD – - Multiple clinical PoC r...
BOSTON and LONDON, July 25, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (R&D) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, ...
News, Short Squeeze, Breakout and More Instantly...
Centessa Pharmaceuticals plc Company Name:
CNTA Stock Symbol:
NASDAQ Market:
Centessa Pharmaceuticals plc Website:
2024-06-21 11:15:04 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for CNTA on June 21, 2024 09:17AM ET. The previous analyst recommendation was Equal-Weight. CNTA was trading at $9.28 at issue of the analyst recommendation. The overall analyst consensus : ...
BOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Fi...
Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 interim analysis planned in 2024 Orexin Agonist Program: Cleared IND and initiated Phase 1 first-in-human clinical trial of ORX750, a highly potent and sel...